Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

NCT06919848 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer (BTC)

Interventions

DRUG: TORIPALIMAB INJECTION(JS001 )
DRUG: Lenvatinib
DRUG: H101
DRUG: FOLFOX

Sponsor

Fudan University